Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan
| Autor: | Takeshi Tsutsumi, Yuya Fujiwara, Naokazu Ibuki, Ryoichi Maenosono, Teruo Inamoto, Haruhito Azuma, Taizo Uchimoto, Hirofumi Uehara, Shin Egawa, Takahiro Kimura, Tomohito Tanaka, Kiyoshi Takahara, Takuya Tsujino, Wataru Fukuokaya, Kazumasa Komura, Tomohisa Matsunaga, Kohei Taniguchi, Yuki Yoshikawa, Hayahito Nomi, Kazuhiro Takahashi, Hajime Hirano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Urology Decision Making Antineoplastic Agents Risk Assessment Disease-Free Survival Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Japan Internal medicine medicine Overall survival Humans Enzalutamide 030212 general & internal medicine Aged business.industry medicine.disease Survival Rate Prostatic Neoplasms Castration-Resistant Abiraterone chemistry Docetaxel 030220 oncology & carcinogenesis Risk stratification Cohort business medicine.drug |
| Zdroj: | BJU International. 127:212-221 |
| ISSN: | 1464-410X 1464-4096 |
| Popis: | OBJECTIVES To assess whether a new risk stratification system according to predictors for overall survival (OS) at the diagnosis of metastatic castration-resistant prostate cancer (mCRPC) could determine treatment outcomes and assist in treatment decision-making. PATIENTS AND METHODS Two independent clinical cohorts of patients, treated with androgen signalling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as a first-line treatment for mCRPC, were used in this study: a derivation cohort (196 patients with mCRPC) and an external validation cohort (211 patients with mCRPC). RESULTS Three independent predictors for OS, including duration of initial androgen deprivation therapy 350 U/dL and haemoglobin level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text